AstraZeneca
Hello World
Hello World
News/ News/ News/ Oncology/ R&D
Merck’s Keytruda flunks another prostate cancer test
Phil Taylor
AstraZeneca, biliary tract cancer, Imfinzi, immuno-oncology, Keytruda, Merck & Co, Oncology, Prostate cancer
0 Comment
Digital/ Oncology/ Views & Analysis/ Views & Analysis/ Views and analysis
Ovarian cancer, Olivia, and the OCC – part one
Nicole Raleigh
AstraZeneca, ENGAGe, ESGO, Olivia, ovarian cancer, Ovarian Cancer Coalition, patients
0 Comment
News/ News/ News/ Oncology/ Sales and Marketing
BMS lawsuit claims AZ’s Imjudo infringes Yervoy patents
Phil Taylor
AstraZeneca, Bristol-Myers Squibb, Imjudo, litigation, patent litigation, Yervoy
0 Comment
Digital/ Patients/ Views & Analysis/ Views & Analysis/ Views and analysis
Driving clinical trial innovation forward with precision medicine
Nicole Raleigh
AstraZeneca, clinical trials, digital health, patient app, precision medicine, Unify
0 Comment
Digital/ News/ News/ News/ News/ Oncology/ Patients
AstraZeneca backs AI-based lung cancer diagnosis pilot in UK
Phil Taylor
AstraZeneca, diagnosis, digital, digital health, lung cancer, Oncology, Qure.ai
0 Comment
Market Access/ News/ News/ News/ Sales and Marketing
EU clears AstraZeneca’s new-form severe asthma drug Tezspire
Phil Taylor
asthma, AstraZeneca, regulatory approval, severe asthma, Tezspire
0 Comment
Market Access/ News/ News/ News/ R&D
Avillion, AstraZeneca asthma rescue treatment given FDA approval
Nicole Raleigh
Airsupra, asthma, AstraZeneca, Avillion, FDA approval, partnership, respiratory
0 Comment
AstraZeneca bolts on blood pressure drug with CinCor takeover
Phil Taylor
AstraZeneca, cardiovascular, chronic kidney disease, CinCor Pharma, Farxiga, hypertension, M&A, nephrology
0 Comment